A new peer-reviewed study adds to the growing evidence that medical marijuana is a highly effective treatment option for chronic pain. Published in the Journal of the American Medical Association (JAMA), the research found that a majority of patients using medical cannabis reported significant pain relief with minimal side effects.
Researchers analyzed data from more than 7,000 adult patients across multiple clinical trials, focusing on individuals with long-term pain conditions such as arthritis, neuropathy, back injuries, and post-surgical pain. The findings showed that medical cannabis use was associated with moderate to substantial reductions in pain severity, improved physical function, and enhanced quality of life.
Unlike opioids, which carry high risks of addiction and overdose, cannabis was well tolerated by most participants. The study also noted lower rates of nausea, dizziness, and cognitive impairment compared to conventional pharmaceutical treatments. Many patients reported being able to reduce or eliminate their use of prescription painkillers after beginning cannabis therapy.
The research reinforces a broader trend in healthcare, where both doctors and patients are turning to cannabis as a safer, plant-based alternative for managing chronic pain—especially in cases where traditional options have failed or caused harmful side effects.
In addition to its therapeutic benefits, the study emphasized the importance of individualized dosing and product selection. Different cannabinoid profiles—such as THC-dominant, CBD-rich, or balanced strains—were found to be effective for different types of pain and patient needs. This highlights the need for patient education and professional guidance when starting cannabis therapy.
With chronic pain affecting an estimated 50 million adults in the U.S., medical cannabis continues to show promise not just as a treatment, but as a potential replacement for high-risk prescriptions that have fueled the nation’s opioid crisis.
For more on topics like these, check this link out PENNSYLVANIA LAWMAKERS SET TO VOTE ON CANNABIS SALES THROUGH STATE-RUN STORES
